FRONT PAGE AMPYRA AUBAGIO AVONEX BETASERON COPAXONE EXTAVIA
Stan's Angels MS News Channel on YouTube GILENYA NOVANTRONE REBIF RITUXAN TECFIDERA TYSABRI
 Daily News for Neuros, Nurses & Savvy MSers: 208,152 Viewers, 8,368 Stories & Studies
Click Here For My Videos, Advice, Tips, Studies and Trials.
Timothy L. Vollmer, MD
Department of Neurology
University of Colorado Health Sciences Center Professor

Co-Director of the RMMSC at Anschutz Medical Center

Medical Director-Rocky Mountain MS Center
Click here to read my columns
Brian R. Apatoff, MD, PhD
Multiple Sclerosis Institute
Center for Neurological Disorders

Associate Professor Neurology and Neuroscience,

Weill Medical College of Cornell University

Clinical Attending in Neurology,
New York-Presbyterian Hospital
CLICK ON THE RED BUTTON BELOW
You'll get FREE Breaking News Alerts on new MS treatments as they are approved
MS NEWS ARCHIVES: by week

HERE'S A FEW OF OUR 6000+ Facebook & MySpace FRIENDS
Timothy L. Vollmer M.D.
Department of Neurology
University of Colorado Health Sciences Center
Co-Director of the RMMSC at Anschutz Medical Center
and
Medical Director-Rocky Mountain MS Center


Click to view 1280 MS Walk photos!

"MS Can Not
Rob You of Joy"
"I'm an M.D....my Mom has MS and we have a message for everyone."
- Jennifer Hartmark-Hill MD
Beverly Dean

"I've had MS for 2 years...this is the most important advice you'll ever hear."
"This is how I give myself a painless injection."
Heather Johnson

"A helpful tip for newly diagnosed MS patients."
"Important advice on choosing MS medication "
Joyce Moore


This page is powered by Blogger. Isn't yours?

Friday

 

More Questions on Vitamin D and MS


























Image Source: PRECISIONNUTRITION

Researchers investigating the question of whether or not vitamin D status could predict disease activity in people with multiple sclerosis (MS) found more questions than answers. Tanuja Chitnis, MD of the Partners Multiple Sclerosis Center, and colleagues published the results of their study in Neurology, Neuroimmunology & Neuroinflammation  in October 2015.
Participants were recruited from the Comprehensive Longitudinal Investigation of Multiple Sclerosis at Brigham and Women’s Hospital (CLIMB). There were three groups of participants: two who were treated with glatiramer acetate (GA) or interferon (IFN) as the first disease-modifying therapy (DMT), and one group of patients on fingolimod (FTY) monotherapy. There were a total of 247 participants in all three groups. The researchers planned to “determine the effect of vitamin D status on clinical and MRI outcomes in patients with MS treated with IFN, GA, and FTY.

Participants were given 25-hydroxyvitamin D (25[OH]D) concentration, which was adjusted for seasonal variation. The primary outcome measurement “was development of a relapse or new T1 gadolinium-enhancing (Gd+) lesion on MRI.” The researchers considered relapses and disability progression as secondary outcomes.

Overall, there was a “decrease of approximately 25% in the hazard of relapse or Gd+ lesion with each tertile increase in 25(OH)D.” The IFN treatment group saw a decrease of about 40%. In the GA group, “there was no significant association between 25(OH)D level and event hazard.” In the FTY cohort there was a “50% reduction in the event hazard with higher 25(OH)D levels.”

The results of this study were mixed. For example, the GA group had the greatest changes in the initial findings, but “then it became the lowest after the initial phase.” The researchers suggest, “one possible explanation for differences in efficacy across treatment groups may be related to immunologic mechanisms of each of the treatments and vitamin D.”

Although the results of this study were not conclusive, it did use a “large, prospective cohort,” and two 25(OH)D measurements were available for the majority of the participants. There were also weaknesses and limitations: timing the initial investigations, being unable to consistently “acquire blood draws on the day of GA or IFN treatment start,” and investigating T2 lesions as an outcome measure.

The researchers conclude, “This study raises the possibility of whether DMT class may modify the effect of vitamin D on disease activity in MS.” They suggest that the results need to be replicated, as well as several avenues for future study. - See more at: http://www.hcplive.com/medical-news/more-questions-on-vitamin-d-and-ms#sthash.Rcs5sFlS.dpuf

Story Source: The above story is based on materials provided by HCPLIVE
Note: Materials may be edited for content and length
Click here to read original article

Labels: ,



Go to Newer News Go to Older News